309 related articles for article (PubMed ID: 37298371)
1. Circulating Tumor DNA in Gastric Adenocarcinoma: Future Clinical Applications and Perspectives.
Grizzi G; Salati M; Bonomi M; Ratti M; Holladay L; De Grandis MC; Spada D; Baiocchi GL; Ghidini M
Int J Mol Sci; 2023 May; 24(11):. PubMed ID: 37298371
[TBL] [Abstract][Full Text] [Related]
2. Liquid biopsy in gastric cancer: predictive and prognostic biomarkers.
Zhang Z; Wu H; Chong W; Shang L; Jing C; Li L
Cell Death Dis; 2022 Oct; 13(10):903. PubMed ID: 36302755
[TBL] [Abstract][Full Text] [Related]
3. ctDNA as promising tool for the assessment of minimal residual disease (MRD) and the need of an adjuvant treatment in gastroesophageal adenocarcinoma.
Piva VM; De Grandis MC; Zuin IS; Angerilli V; Nappo F; Alfieri R; Ahcene Djaballah S; Murgioni S; Bergamo F; Fassan M; Valmasoni M; Lonardi S
Updates Surg; 2023 Feb; 75(2):305-312. PubMed ID: 36272058
[TBL] [Abstract][Full Text] [Related]
4. Molecular characterization of ctDNA from Chinese patients with advanced gastric adenocarcinoma reveals actionable alterations for targeted and immune therapy.
Zhang M; Qi C; Wang Z; Chen H; Zhao X; Zhang X; Zhou Y; Gao C; Bai Y; Jia S; Ji J
J Mol Med (Berl); 2021 Sep; 99(9):1311-1321. PubMed ID: 34057552
[TBL] [Abstract][Full Text] [Related]
5. ctDNA analysis in the personalized clinical management of gastroesophageal adenocarcinoma: turning hope into reality.
Salati M; Venetis K; Fassan M; Malapelle U; Pagni F; Sajjadi E; Fusco N; Ghidini M
Future Oncol; 2021 Nov; 17(33):4607-4618. PubMed ID: 34406032
[TBL] [Abstract][Full Text] [Related]
6. Making the Rounds: Exploring the Role of Circulating Tumor DNA (ctDNA) in Non-Small Cell Lung Cancer.
Shields MD; Chen K; Dutcher G; Patel I; Pellini B
Int J Mol Sci; 2022 Aug; 23(16):. PubMed ID: 36012272
[TBL] [Abstract][Full Text] [Related]
7. Detecting liquid remnants of solid tumors treated with curative intent: Circulating tumor DNA as a biomarker of minimal residual disease (Review).
Chen H; Zhou Q
Oncol Rep; 2023 May; 49(5):. PubMed ID: 37052271
[TBL] [Abstract][Full Text] [Related]
8. Deep sequencing of circulating tumor DNA detects molecular residual disease and predicts recurrence in gastric cancer.
Yang J; Gong Y; Lam VK; Shi Y; Guan Y; Zhang Y; Ji L; Chen Y; Zhao Y; Qian F; Chen J; Li P; Zhang F; Wang J; Zhang X; Yang L; Kopetz S; Futreal PA; Zhang J; Yi X; Xia X; Yu P
Cell Death Dis; 2020 May; 11(5):346. PubMed ID: 32393783
[TBL] [Abstract][Full Text] [Related]
9. Circulating Tumor DNA-Based Testing and Actionable Findings in Patients with Advanced and Metastatic Pancreatic Adenocarcinoma.
Botrus G; Kosirorek H; Sonbol MB; Kusne Y; Uson Junior PLS; Borad MJ; Ahn DH; Kasi PM; Drusbosky LM; Dada H; Surapaneni PK; Starr J; Ritter A; McMillan J; Wylie N; Mody K; Bekaii-Saab TS
Oncologist; 2021 Jul; 26(7):569-578. PubMed ID: 33555095
[TBL] [Abstract][Full Text] [Related]
10. Tumor-specific genetic aberrations in cell-free DNA of gastroesophageal cancer patients.
Koldby KM; Mortensen MB; Detlefsen S; Pfeiffer P; Thomassen M; Kruse TA
J Gastroenterol; 2019 Feb; 54(2):108-121. PubMed ID: 30242476
[TBL] [Abstract][Full Text] [Related]
11. Utilizing circulating tumour DNA as a prognostic predictor of gastric cancer: a meta-analysis.
Min L; Chen J; Yu M; Yang K; Liu D
Biomarkers; 2023 Dec; 28(5):427-436. PubMed ID: 37036017
[No Abstract] [Full Text] [Related]
12. Liquid biopsy in lymphoma: Molecular methods and clinical applications.
Cirillo M; Craig AFM; Borchmann S; Kurtz DM
Cancer Treat Rev; 2020 Dec; 91():102106. PubMed ID: 33049623
[TBL] [Abstract][Full Text] [Related]
13. Dynamic Treatment Stratification Using ctDNA.
Vidal J; Taus A; Montagut C
Recent Results Cancer Res; 2020; 215():263-273. PubMed ID: 31605234
[TBL] [Abstract][Full Text] [Related]
14. Quantitative and Qualitative Analysis of Blood-based Liquid Biopsies to Inform Clinical Decision-making in Prostate Cancer.
Casanova-Salas I; Athie A; Boutros PC; Del Re M; Miyamoto DT; Pienta KJ; Posadas EM; Sowalsky AG; Stenzl A; Wyatt AW; Mateo J
Eur Urol; 2021 Jun; 79(6):762-771. PubMed ID: 33422353
[TBL] [Abstract][Full Text] [Related]
15. Circulating Tumor DNA in the Management of Early-Stage Breast Cancer.
Vlataki K; Antonouli S; Kalyvioti C; Lampri E; Kamina S; Mauri D; Harissis HV; Magklara A
Cells; 2023 Jun; 12(12):. PubMed ID: 37371043
[TBL] [Abstract][Full Text] [Related]
16. Using Circulating Tumor DNA in Colorectal Cancer: Current and Evolving Practices.
Malla M; Loree JM; Kasi PM; Parikh AR
J Clin Oncol; 2022 Aug; 40(24):2846-2857. PubMed ID: 35839443
[TBL] [Abstract][Full Text] [Related]
17. The potential of liquid biopsy in the management of cancer patients.
Markou A; Tzanikou E; Lianidou E
Semin Cancer Biol; 2022 Sep; 84():69-79. PubMed ID: 35331850
[TBL] [Abstract][Full Text] [Related]
18. Circulating Tumor DNA Sequencing Analysis of Gastroesophageal Adenocarcinoma.
Maron SB; Chase LM; Lomnicki S; Kochanny S; Moore KL; Joshi SS; Landron S; Johnson J; Kiedrowski LA; Nagy RJ; Lanman RB; Kim ST; Lee J; Catenacci DVT
Clin Cancer Res; 2019 Dec; 25(23):7098-7112. PubMed ID: 31427281
[TBL] [Abstract][Full Text] [Related]
19. Use of Circulating Tumor DNA for Cancer Immunotherapy.
Snyder A; Morrissey MP; Hellmann MD
Clin Cancer Res; 2019 Dec; 25(23):6909-6915. PubMed ID: 31285372
[TBL] [Abstract][Full Text] [Related]
20. Circulating tumor DNA (ctDNA) to evaluate minimal residual disease (MRD), treatment response, and posttreatment prognosis in pancreatic adenocarcinoma.
Ueberroth BE; Jones JC; Bekaii-Saab TS
Pancreatology; 2022 Sep; 22(6):741-748. PubMed ID: 35725696
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]